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ABSTRACT: A series of diterpenoid derivatives based on podocarpic acid were synthesized and
evaluated as anti-influenza A virus agents. Several of the novel podocarpic acid derivatives exhibited
nanomolar activities against an H1N1 influenza A virus (A/Puerto Rico/8/34) that was resistant to two
anti-influenza drugs, oseltamivir and amantadine. This class of compounds inhibits the influenza virus by
targeting the viral hemagglutinin-mediated membrane fusion. These results indicated that podocarpic
acid derivatives may serve as potential drug candidates to fight drug-resistant influenza A virus infections.
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Influenza virus infection causes a contagious respiratoryillness known as the flu. During the peak of the flu season,
5−10% of adults and 20−30% of children may be affected
worldwide. Severe illness and death can occur especially among
high risk populations.1 Influenza type A virus (IAV) infections
have caused several major pandemics in the past with grave
impacts on global health.2−5 The IAV genome contains eight
negative-stranded RNA segments that encode for 11 viral
proteins including hemagglutinins (HA1; HA2), matrix 1 (M1),
matrix 2 (M2), nucleoprotein (NP), nonstructural protein 1
(NSP), polymerase acidic protein (PA), polymerase basic
proteins (PB1; PB2; PB1-F2), and neuraminidase (NA).6 IAVs
are classified into subtypes based on combinations of the viral
surface proteins HA and NA. The H1N1 and H3N2 are two
currently circulating IAV subtypes. IAVs have evolved a
promiscuous entry process that uses sialic acid-containing
molecules as receptors.6 This allows the virus to infect host cells
across various animal species. Avian influenza viruses, such as
H5N1, have been circulating in recent years. Although the
transmission of avian flu viruses to humans is inefficient, the
viruses are highly pathogenic and may pose a threat if they
acquire the ability of efficient human-to-human transmission.
Two NA inhibitors, oseltamivir and zanamivir, are the
current FDA-approved drugs recommended by the US CDC
for clinical use against recently circulating influenza viruses.7
However, emerging drug resistance and limited effectiveness
associated with the NA inhibitors have been reported.8−10
Older drugs such as amantadine and rimantadine that target the
M2 ion channel of the virus were approved for treatment and
prevention of IAV infection. However, many strains of the
influenza virus, such as the 2009 H1N1 influenza virus, are
resistant to these two drugs.11 Thus, novel anti-influenza virus
agents are needed to circumvent the limitations of currently
available drugs.
In an effort to identify new anti-IAV agents, we have
screened over a thousand natural products for their potential
activity against IAV. As a result, several classes of natural
products were identified to have anti-IAV activity, including
quinolizidine alkyloids.12 In this study, we found that two
diterpenoids, (+)-podocarpic acid (PA) and (+)-totarol, could
inhibit IAV at low micromolar concentrations. PA and totarol
are both abietane type tricyclic phenolic diterpenoids (Figure
1) and can be found in resins from the New Zealand conifers
Dacrydium cupressinum13 and Podocarpus totara.14 Several
different biological activities were reported for these
diterpenoids including liver X receptor agonist activity and
cytokine release inhibition activity for PA derivatives.15−18
Totarol was reported to have antiplasmodial, antifungal, and
antimicrobial activities.19−23 Methyl O-methyl-7-ketopodocar-
pate, a PA analogue, was identified as an inhibitor of influenza
virus that targets the hemagglutinin-mediated membrane
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Figure 1. Structure of diterpenoids.
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fusion.24 To further improve the anti-IAV activity of abietane-
type diterpenoids, we synthesized and evaluated 22 derivatives
for their anti-IAV activities, including a variety of esters and
amides (2, 3, 22, 23) and O-acyl (4−9, 12−19) and O-alkyl
derivatives (10, 11, 20, and 21).
The synthesis of novel diterpenoid derivatives described
herein is outlined in Scheme 1. PA derivatives 2 and 19−21
were known compounds synthesized by the previously reported
methods.25,26 Benzyl ester (3) was prepared by treating PA
with benzyl bromide in the presence of potassium carbonate
under microwave heating. PA was converted into compound 22
by treatment with the coupling reagent BOP in the presence of
methylamine hydrochloride and THF. Compounds 4, 5, and 23
were synthesized by coupling acrylic acid with either 2, 3, or 22.
Compounds 6−9 were obtained by coupling the phenol with
corresponding dicarboxylic acid anhydride under sodium
hydride mediated-esterification. Treatment of methyl or benzyl
podocarpate with 3-bromopropionic acid in the presence of
sodium hydride resulted in phenolic ether compounds 10 and
11. Microwave heating of different ω-bromocarboxylic acid or
other carboxylic acid reagents with methyl podocarpate (2) in
the presence of DCC and DMAP resulted in corresponding
esters 12−18. Compound 19 was synthesized by treating 2
with acetic anhydride in the presence of pyridine at room
temperature.
The new diterpenoid derivatives as well as PA and totarol
were tested for their activity against a cell-line adapted influenza
virus A/Puerto Rico/8/34 (H1N1) (PR8) infection of Madin-
Darby canine kidney (MDCK) cells. The PR8 virus is resistant
to both oseltamivir and amantidine with an EC50 greater than
20 μM, as shown in Table 1. PA inhibited the PR8 virus with
moderate potency at an EC50 of 18.2 μM. The methyl
podocarpate (2) and its O-acetyl derivative (19) improved anti-
IAV potency over PA by approximately 100-fold with an EC50
at 0.16 and 0.14 μM, respectively. The benzyl ester (3),
however, was only ten times more potent than PA. Amide
modification on the carboxylic acid caused a great loss of
activity as seen in 22. Modifications of the phenol group (R1)
on compound 2 or 3 to an ester or ether did not improve anti-
IAV potency, though the ester compounds (4, 5, 7, 8, 12−18)
did remain active with EC50s ranging from 0.15 to 0.64 μM.
The compounds with an ether substituent at R1 and with a
propionic acid side chain similar to that of 7 suffered further
loss of activity as seen in 10 and 11. Meanwhile, compound 20
with a methoxyl substituent at R1 remained relatively active
with an EC50 at 0.73 μM. In addition, the previously reported
C7 keto analogue (21)24 was about 5 times less active against
the PR8 virus than its precursor 20. Totarol (24) possesses a
similar abietane scaffold to that of PA but with different
Scheme 1. Synthesis of Podocarpic Acid Derivativesa
aReagents and conditions: (a) NaOH, MeOH, Me2SO4, rt, 30 min, 70
°C, 15 min; (b) BnBr, K2CO3, Ac2O, 90 °C, MW, 30 min; (c) acrylic
acid, DCC, DMAP, DCM, 90 °C, 15 min; (d) NaH, DMF, succinic or
glutaric anhydride, 0 °C, 30 min; (e) NaH, DMF, BrCH2CH2COOH,
rt, overnight; (f) RCOOH, DCC, DMAP, DCM, 110 °C, MW, 45 min
or anhydride, pyridine, rt, overnight; (g) NaH, Me2SO4, 0 °C, 50 min,
rt, overnight; (h) BOP, MeNH2·HCl, TEA, THF, rt, overnight; (i)
CrO3, Ac2O, AcOH, 0 °C, 1 h, rt, overnight.
Table 1. Anti-IAV Activities of Diterpenoidsa
aAn influenza virus strain A/Puerto Rico/8/1934, PR8, was used in
the assays. bConcentration (μM) required to protect cells from the
cytocidal effect of PR8 by 50%. cThe EC50 (μM) is presented as mean
± SD from at least three independent tests. dConcentration (μM) that
reduced the viability of MDCK cells by 50%. eKnown compounds.
fNA, Not active.
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substitutions on C4 and the aromatic ring. Totarol was about 5
times more potent than PA against the PR8 virus.
We next investigated whether compounds that were active
against the PR8 virus could also inhibit an H3N2 virus A/Hong
Kong/8/68 (VR1679), an oseltamivir sensitive IAV. None of
the tested podocarpate derivatives inhibited the VR1679 virus
by greater than 50% at a concentration as high as 20 μM using
the cytocidal protection assay described in Table 1.
Totarol was identified as having anti-VR1679 activity in a
process of screening new anti-IAV natural products with
structures similar to podocarpates. Because of the weak activity
of podocarpate derivatives against the VR1679 virus, confocal
microscopy was used to study the anti-IAV activity of the
compounds and to compare their relative potency against the
PR8 and VR1679 viruses. The viral infection was established in
the presence of totarol or the PA derivative 12. The virus
infected cells were stained green with an antibody against IAV
NP. As shown in the confocal microscopic images in Figure 2,
VR1679 efficiently infected MDCK cells in the absence of anti-
IAV compounds (Control). Cells treated with 10 μM of 12
showed strong inhibition of PR8 infection and mild inhibition
of VR1679. However, totarol was clearly more potent than 12
against VR1679 at the same concentration. Even though totarol
was approximately 15-fold less potent than 12 against PR8
(Table 1), totarol was more potent than 12 in inhibiting the
H3N2 VR1679. These results suggest that totarol displays less
subtype specific antiviral activity against H1N1 and H3N2
viruses than compound 12.
Compound 21 is a podocarpate previously shown to target
the HA of IAV for its moderate antiviral activity.24 To
determine if the synthesized podocarpate derivatives also target
the HA of IAV, compound 4 was tested in an HA-mediated
hemolysis assay. Oseltamivir, a neuraminidase inhibitor, was
used as a negative control. As expected, oseltamivir did not
inhibit the PR8-HA mediated hemolysis. However, compound
4 significantly inhibited the HA-mediated hemolysis in a dose-
dependent manner (Figure 3). This result suggests that
compound 4 inhibited IAV PR8 by targeting HA.
The synthesized podocarpic acid derivatives contain one or
two ester linkages, which may be subjected to degradation by
serum esterases. To test their plasma stabilities, two of the
potent podocarpic acid derivatives, 2 (a mono ester) and 19 (a
diester), were incubated with 80% human plasma at 37 °C for
various durations shown in Figure 4. The initial and remaining
quantities of parent compounds at various time points were
determined using reverse phase HPLC. The results indicated
that 2 with a methyl ester was relatively stable with 86% of the
parent compound intact after 2 h of incubation in human
plasma (Figure 4). However, the phenolic ester in 19 was
unstable under this condition with only 30% of parental
compound remaining after 10 min. This result suggests that
evaluation of plasma stability of podocarpic acid derivatives may
be important in selecting compounds for further preclinical
drug development.
In summary, among the synthesized PA derivatives, methyl
podocarpate (2) and its O-acetyl derivative (19) displayed the
most potent activity against the oseltamivir-resistant PR8
infection of MDCK cells with an EC50 of about 160 and 140
nM, respectively. The potency of these two compounds is
approximately 20-fold greater than that of the previously
reported podocarpate compound 21. The target of PA
derivatives appears to be the HA of the influenza virus. This
is consistent with a previous study by Staschke et al. that the
podocarpate, compound 21, inhibited influenza viruses by
blocking HA-mediated membrane fusion.24 The hemagglutinin
protein is crucial for viral entry. Although the synthesized PA
derivatives could potently inhibit the PR8 virus, they were
Figure 2. Effects of compound 12 and totarol on IAV infected MDCK
cells. MDCK cells were infected with PR8 or VR1679 at MOI = 1 in
the presence of 10 μM of 12 or totarol for 6 h. The cells were stained
with FITC conjugated anti-NP antibodies (green) and DAPI (nuclear
stain, blue). The top panel (control) shows viral infection in the
absence of the compounds. The confocal images were acquired using a
Nikon A1R confocal microscope.
Figure 3. Podocarpates inhibited PR8-HA-mediated hemolysis. A
hemolysis inhibition assay was carried out to evaluate the effects of PA
derivatives on the HA-mediated hemolysis of chicken erythrocytes.27
Compound 4 or oseltamivir was mixed with the PR8 virus for 30 min
at room temperature before adding chicken erythrocytes. The mixture
was then incubated at 37 °C for another 30 min. To trigger hemolysis,
the suspension containing the erythrocyte-virus-compound mixture
was acidified to pH = 5.2 with a 0.15 M sodium acetate buffer.
Hemolysis was quantified by measuring the OD540 of supernatants.
The HA-mediated hemolysis in the absence of compounds is defined
as 100% hemolysis. The results represent the average of two
independent tests.
Figure 4. Stability of podocarpic acid derivatives in human plasma.
Benfluorex (BFR) was used as a control.28 Each data point represents
the average of a duplicated experiment. Detailed methodology was
included in the Supporting Information.
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significantly less active against the H3N2 virus VR1979.
Totarol, however, likely has a broader spectrum of anti-IAV
activity. Therefore, totarol is a promising new scaffold for the
synthesis of anti-IAV agents with increased potency and
breadth of anti-IAV activity.
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